Intrahepatic Islet Transplant in the Mouse: Functional and Morphological Characterization

Although in a clinical setting islet transplantation is normally performed by percutaneous intrahepatic infusion, the kidney capsule has been the site of choice in nearly all the studies using mice. In the present study, we extensively characterized the mouse model of intraportally transplanted islets with the purpose to propose it as a model to study islet transplantation. C57BL/6 (n = 78) and BALB/C (n = 53) recipients were transplanted with 400 autologous islets alternatively through the portal vein (PV-Tx) or under the kidney capsule (KC-Tx). Glucose concentration during the first hour after syngeneic islet infusion was associated with subsequent long-term function confirming that early events have long-term effects on graft function. In both strains tested the probability to achieve islet function was significantly lower for PV-Tx than KC-Tx. Also in allogeneic models (C57BL/6 to BALB/C, n = 104; BALB/C to C57BL/6, n = 77) the probability to achieve primary function was significantly lower for PV-Tx than KC-Tx and the site of transplantation significantly affected the graft survival. Histological evaluation of livers showed the presence of features (embolism, thrombosis, focal areas of liver necrosis) that are absent in the kidney subcapsular site. Finally, significant differences in the outcome of PV-Tx were observed between the Th type 1 inflammatory-prone C57BL/6 mouse and the type 2 inflammatory-prone BALB/C mouse. Intraportal islet graft model has some features that are more similar to human clinical islet transplantation and should be used as a model to study not only engraftment but also mechanisms of immune suppression and immune tolerance.

[1]  R. Bretzel,et al.  Pancreatic islet xenografts at two different transplantation sites (renal subcapsular versus intraportal): comparison of graft survival and morphology. , 2009, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[2]  E. Bonifacio,et al.  Relevance of Hyperglycemia on the Timing of Functional Loss of Allogeneic Islet Transplants: Implication for Mouse Model , 2007, Transplantation.

[3]  C. Bradfield,et al.  Liver Deformation in Ahr-Null Mice: Evidence for Aberrant Hepatic Perfusion In Early Development , 2006, Molecular Pharmacology.

[4]  F. Alvarez,et al.  Type 2 autoimmune hepatitis murine model: the influence of genetic background in disease development. , 2006, Journal of autoimmunity.

[5]  P. Popovich,et al.  Comparative analysis of lesion development and intraspinal inflammation in four strains of mice following spinal contusion injury , 2006, The Journal of comparative neurology.

[6]  M. Hara,et al.  Liver Ischemia Contributes to Early Islet Failure Following Intraportal Transplantation: Benefits of Liver Ischemic‐Preconditioning , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[7]  O. Ohara,et al.  Vα14 NK T cell–triggered IFN-γ production by Gr-1+CD11b+ cells mediates early graft loss of syngeneic transplanted islets , 2005, The Journal of experimental medicine.

[8]  E. Hiyama,et al.  Hepatic regeneration promotes engraftment of intraportally transplanted islet cells. , 2005, Surgery.

[9]  K. Ekdahl,et al.  Tissue factor produced by the endocrine cells of the islets of Langerhans is associated with a negative outcome of clinical islet transplantation. , 2005 .

[10]  Rajesh Balkrishnan,et al.  Transaminitis after pancreatic islet transplantation. , 2005, Journal of the American College of Surgeons.

[11]  M. Salvioni,et al.  Technique, complications, and therapeutic efficacy of percutaneous transplantation of human pancreatic islet cells in type 1 diabetes: the role of US. , 2005, Radiology.

[12]  A. Shapiro,et al.  The Portal Immunosuppressive Storm: Relevance to Islet Transplantation? , 2005, Therapeutic drug monitoring.

[13]  G. Pacini,et al.  Beta-cell-targeted expression of a dominant-negative mutant of hepatocyte nuclear factor-1alpha in mice: diabetes model with beta-cell dysfunction partially rescued by nonglucose secretagogues. , 2004, Diabetes.

[14]  José A Fernández,et al.  Activated protein C preserves functional islet mass after intraportal transplantation: a novel link between endothelial cell activation, thrombosis, inflammation, and islet cell death. , 2004, Diabetes.

[15]  E. Bonifacio,et al.  Tissue factor and CCL2/monocyte chemoattractant protein-1 released by human islets affect islet engraftment in type 1 diabetic recipients. , 2004, The Journal of clinical endocrinology and metabolism.

[16]  M. Hara,et al.  A mouse model for studying intrahepatic islet transplantation. , 2004, Transplantation.

[17]  A. Shapiro,et al.  Prevalence of hepatic steatosis after islet transplantation and its relation to graft function. , 2004, Diabetes.

[18]  W. Rau,et al.  Disseminated periportal fatty degeneration after allogeneic intraportal islet transplantation in a patient with type 1 diabetes mellitus: a case report. , 2004, Transplantation proceedings.

[19]  O. Korsgren,et al.  Intraportal pig islet xenotransplantation into athymic mice as an in vivo model for the study of the instant blood‐mediated inflammatory reaction , 2004, Xenotransplantation.

[20]  P. Argibay,et al.  Effect of the Embolization of Completely Unpurified Islets on Portal Vein Pressure and Hepatic Biochemistry in Clinical Practice , 2004, Cell transplantation.

[21]  C. McDonald,et al.  Changes in liver enzymes after clinical islet transplantation1 , 2003, Transplantation.

[22]  K. Ekdahl,et al.  Production of tissue factor by pancreatic islet cells as a trigger of detrimental thrombotic reactions in clinical islet transplantation , 2002, The Lancet.

[23]  K Thomaseth,et al.  Contribution to glucose tolerance of insulin-independent vs. insulin-dependent mechanisms in mice. , 2001, American journal of physiology. Endocrinology and metabolism.

[24]  F. Bertuzzi,et al.  Effects of cryopreservation on in vitro and in vivo long-term function of human islets. , 1999, Transplantation.

[25]  P. Morris,et al.  The long-term metabolic function of intraportal and renal subcapsular islet isografts and the effect on glomerular basement membrane thickness in rats , 1995, Diabetologia.

[26]  D. Sutherland,et al.  PROLONGED SURVIVAL OF INTRAPORTAL VERSUS SUBRENAL CAPSULAR TRANSPLANTED ISLET ALLOGRAFTS , 1987, Transplantation.

[27]  C. Meyer Islet transplantation. , 2007, The New England journal of medicine.

[28]  M. Taniguchi,et al.  Natural killer T-cells participate in rejection of islet allografts in the liver of mice. , 2006, Diabetes.

[29]  N. Barshes,et al.  islet transplantation: implications for intrahepatic grafts , 2022 .